Veracity Neuroscience, LLC
Welcome,         Profile    Billing    Logout  
 13 Trials 
38 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
LeDoux, Mark S
TOPAZ, NCT03924414: Trial of Parkinson's and Zoledronic Acid

Active, not recruiting
4
2650
US
Zoledronic Acid 5Mg/Bag 100Ml Inj, Reclast, Placebo
California Pacific Medical Center Research Institute, National Institute on Aging (NIA), University of California, San Francisco, Duke University, University of Pittsburgh, Parkinson's Foundation
Parkinson Disease, Osteoporosis, Parkinsonism, Parkinson's Disease and Parkinsonism, Atypical Parkinsonism, Progressive Supranuclear Palsy, Multiple System Atrophy, Vascular Parkinsonism, Dementia with Lewy Bodies
10/25
10/25
NCT05357989 / 2022-001542-38: A Double-blind Study to Investigate Efficacy and Safety of Buntanetap Compared With Placebo in Participants With Early PD

Completed
3
523
Europe, US
buntanetap/posiphen, Posiphen Tartrate, ANVS401, Placebo
Annovis Bio Inc., TFS Trial Form Support
Parkinson's Disease, Idiopathic
12/23
12/23
TEMPO-3, NCT04542499 / 2019-002951-40: Flexible-Dose, Adjunctive Therapy Trial in Adults With Parkinson's Disease With Motor Fluctuations

Completed
3
507
Europe, Canada, US, RoW
Tavapadon, PF-06649751, CVL-751, Placebo
Cerevel Therapeutics, LLC
Parkinson Disease
01/24
02/24
TEMPO-2, NCT04223193 / 2019-002950-22: Flexible-Dose Trial in Early Parkinson's Disease (PD)

Completed
3
304
Europe, US, RoW
Tavapadon, PF-06649751, CVL-751, Placebo
Cerevel Therapeutics, LLC
Parkinson Disease
10/24
10/24
ORION, NCT06122662: AMX0035 and Progressive Supranuclear Palsy

Active, not recruiting
2/3
110
Europe, US
AMX0035, Placebo
Amylyx Pharmaceuticals Inc.
Progressive Supranuclear Palsy, PSP, Neurodegenerative Diseases, Atypical Parkinsonism
04/26
11/29
NCT06006247: Early Parkinson's Disease Monotherapy With CVN424

Completed
2
62
US
CVN424 150 mg, Placebo
Cerevance Beta, Inc.
Parkinson's Disease
01/25
02/25
Isaacson, Stuart
LIGHTHOUSE, NCT05418673 / 2022-000747-77: A Study to Assess if BIIB122 Tablets Are Safe and Can Slow Worsening of Early-Stage Parkinson's Disease in Participants With Specific LRRK2 Genetic Variants Between the Ages of 30 and 80 Using the Movement Disorder Society-Unified Parkinson's Disease Rating Scale

Terminated
3
7
Europe, US
BIIB122, DNL151, BIIB122-Matching Placebo
Biogen, Denali Therapeutics Inc.
Parkinson Disease
07/23
07/23
NCT05357989 / 2022-001542-38: A Double-blind Study to Investigate Efficacy and Safety of Buntanetap Compared With Placebo in Participants With Early PD

Completed
3
523
Europe, US
buntanetap/posiphen, Posiphen Tartrate, ANVS401, Placebo
Annovis Bio Inc., TFS Trial Form Support
Parkinson's Disease, Idiopathic
12/23
12/23
TEMPO-3, NCT04542499 / 2019-002951-40: Flexible-Dose, Adjunctive Therapy Trial in Adults With Parkinson's Disease With Motor Fluctuations

Completed
3
507
Europe, Canada, US, RoW
Tavapadon, PF-06649751, CVL-751, Placebo
Cerevel Therapeutics, LLC
Parkinson Disease
01/24
02/24
TEMPO-1, NCT04201093 / 2019-002949-38: Fixed-Dose Trial in Early Parkinson's Disease (PD)

Completed
3
522
Europe, Canada, US, RoW
Tavapadon, PF-06649751, CVL-751, Placebo
Cerevel Therapeutics, LLC
Parkinson Disease
06/24
06/24
REFOCUS-ALZ, NCT05026177: Simufilam 50 mg or 100 mg for Mild-to-Moderate Alzheimer's Disease

Terminated
3
1125
Canada, US, RoW
Simufilam, PTI-125, Placebo
Cassava Sciences, Inc., Premier Research Group plc
Alzheimer Disease
12/24
12/24
ORION, NCT06122662: AMX0035 and Progressive Supranuclear Palsy

Active, not recruiting
2/3
110
Europe, US
AMX0035, Placebo
Amylyx Pharmaceuticals Inc.
Progressive Supranuclear Palsy, PSP, Neurodegenerative Diseases, Atypical Parkinsonism
04/26
11/29
NCT03655236: PROSEEK: A Phase 2 Study In Early Parkinson's Disease Patients Evaluating The Safety And Efficacy Of Abl Tyrosine Kinase Inhibition Using K0706

Terminated
2
513
Europe, US, RoW
K0706, placebo
Sun Pharma Advanced Research Company Limited
Early Parkinson Disease
04/24
06/24
SHIMMER, NCT05225415: Study to Evaluate the Safety, Tolerability and Efficacy of CT1812 in Subjects with Mild to Moderate Dementia with Lewy Bodies

Completed
2
130
US
CT1812
Cognition Therapeutics, National Institute on Aging (NIA)
Dementia with Lewy Bodies
11/24
11/24
NCT06006247: Early Parkinson's Disease Monotherapy With CVN424

Completed
2
62
US
CVN424 150 mg, Placebo
Cerevance Beta, Inc.
Parkinson's Disease
01/25
02/25
LRRK2-PD, NCT06602193: Safety and Pharmacodynamic Effects of BIIB122 in Participants With LRRK2-Associated Parkinson's Disease

Recruiting
2
50
Europe, US
BIIB122 225 mg, DNL151, BIIB122-Matching Placebo
Denali Therapeutics Inc., Biogen
Parkinson Disease
04/26
02/28
NEULARK, NCT06680830: A Phase 2 Study of NEU-411 in Companion Diagnostic-Positive Participants with Early Parkinson's Disease

Recruiting
2
150
US
NEU-411, Placebo
Neuron23 Inc.
Parkinson Disease, Parkinson, Idiopathic Parkinson Disease, Early Parkinson Disease (Early PD), Parkinson Disease, Idiopathic
09/26
09/27
LUMA, NCT05348785 / 2021-004849-20: A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson's Disease in Adults Between the Ages of 30 and 80

Recruiting
2
640
Europe, Canada, Japan, US, RoW
BIIB122, DNL151, BIIB122-Matching Placebo
Biogen, Denali Therapeutics Inc.
Parkinson Disease
12/25
12/25
NCT05923866: A Phase 2 Study of ONO-2808 in Patients With Multiple System Atrophy

Active, not recruiting
2
92
Japan, US
ONO-2808, Placebo
Ono Pharmaceutical Co. Ltd
Multiple System Atrophy (MSA)
08/25
08/25
ACTIVATE, NCT05819359: Efficacy, Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BIA 28-6156 in GBA-PD

Active, not recruiting
2
237
Europe, Canada, US
BIA 28-6156 10 mg, BIA 28-6156 60 mg, Placebo
Bial R&D Investments, S.A.
Parkinson's Disease
03/26
07/26
NCT04680065: GDNF Gene Therapy for Multiple System Atrophy

Recruiting
1
9
US
AAV2-GDNF gene therapy, Sham (Placebo) Surgery
Brain Neurotherapy Bio, Inc.
Multiple System Atrophy
12/25
12/28
NCT06219629: Parkinson's Disease Progression Study

Active, not recruiting
N/A
82
US
Koneksa Health, Merck Sharp & Dohme LLC, Regeneron Pharmaceuticals
Parkinson Disease
02/26
02/26
TRANQUIL, NCT06235190: Assessment of the Safety and Efficacy of the Felix NeuroAI Wristband in Essential Tremor

Active, not recruiting
N/A
126
US, RoW
Felix NeuroAI Wristband, Sham Device
Fasikl Inc.
Essential Tremor
10/24
11/25
NCT04994015: Parkinson's Foundation PD GENEration Genetic Registry

Recruiting
N/A
25000
Canada, US, RoW
Lab Assay for seven genetic variants for Parkinson's Disease
Parkinson's Foundation, Indiana University, Fulgent Genetics, The Parkinson Study Group
Parkinson's Disease
12/24
06/25
NCT05699460: Pre-Gene Therapy Study in Parkinson's Disease and Multiple System Atrophy

Active, not recruiting
N/A
150
Europe, US
This is an observational study.
Asklepios Biopharmaceutical, Inc.
Parkinson's Disease, Multiple System Atrophy, Parkinson Variant, Multiple System Atrophy
08/25
10/25
ROPAD, NCT03866603: Rostock International Parkinson's Disease Study

Active, not recruiting
N/A
25000
Europe, Canada, US, RoW
CENTOGENE GmbH Rostock
Parkinson´s Disease
12/25
12/25
PPMI, NCT04477785: Clinical - Establishing a Deeply Phenotyped PD Cohort

Recruiting
N/A
4500
Europe, Canada, US, RoW
Michael J. Fox Foundation for Parkinson's Research, Institute for Neurodegenerative Disorders
Parkinson Disease
12/33
12/33
Apetauerova, Diana
ORION, NCT06122662: AMX0035 and Progressive Supranuclear Palsy

Active, not recruiting
2/3
110
Europe, US
AMX0035, Placebo
Amylyx Pharmaceuticals Inc.
Progressive Supranuclear Palsy, PSP, Neurodegenerative Diseases, Atypical Parkinsonism
04/26
11/29
Wszolek, Zbigniew
ORION, NCT06122662: AMX0035 and Progressive Supranuclear Palsy

Active, not recruiting
2/3
110
Europe, US
AMX0035, Placebo
Amylyx Pharmaceuticals Inc.
Progressive Supranuclear Palsy, PSP, Neurodegenerative Diseases, Atypical Parkinsonism
04/26
11/29
NCT05923866: A Phase 2 Study of ONO-2808 in Patients With Multiple System Atrophy

Active, not recruiting
2
92
Japan, US
ONO-2808, Placebo
Ono Pharmaceutical Co. Ltd
Multiple System Atrophy (MSA)
08/25
08/25
NCT04529252: Investigating the Genetic and Phenotypic Presentation of Ataxia and Nucleotide Repeat Diseases

Recruiting
N/A
1000
US
Specimen collection
Mayo Clinic
Spinocerebellar Ataxias, Cerebellar Ataxia, Nucleotide Repeat Disease
12/26
12/26
NCT04503213: A Study to Assess CSF1R-related Leukoencephalopathy After Stem Cell Transplantation

Enrolling by invitation
N/A
20
US
Mayo Clinic
CSF1R-related Leukoencephalopathy, ALSP, POLD, Hematopoietic Stem Cell Transplantation
12/25
12/25
Ly, Helen
NCT05357989 / 2022-001542-38: A Double-blind Study to Investigate Efficacy and Safety of Buntanetap Compared With Placebo in Participants With Early PD

Completed
3
523
Europe, US
buntanetap/posiphen, Posiphen Tartrate, ANVS401, Placebo
Annovis Bio Inc., TFS Trial Form Support
Parkinson's Disease, Idiopathic
12/23
12/23
Laud, Arjun
ORION, NCT06122662: AMX0035 and Progressive Supranuclear Palsy

Active, not recruiting
2/3
110
Europe, US
AMX0035, Placebo
Amylyx Pharmaceuticals Inc.
Progressive Supranuclear Palsy, PSP, Neurodegenerative Diseases, Atypical Parkinsonism
04/26
11/29
NCT05923866: A Phase 2 Study of ONO-2808 in Patients With Multiple System Atrophy

Active, not recruiting
2
92
Japan, US
ONO-2808, Placebo
Ono Pharmaceutical Co. Ltd
Multiple System Atrophy (MSA)
08/25
08/25
ACTIVATE, NCT05819359: Efficacy, Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BIA 28-6156 in GBA-PD

Active, not recruiting
2
237
Europe, Canada, US
BIA 28-6156 10 mg, BIA 28-6156 60 mg, Placebo
Bial R&D Investments, S.A.
Parkinson's Disease
03/26
07/26
Holms, Freddrenia
ORION, NCT06122662: AMX0035 and Progressive Supranuclear Palsy

Active, not recruiting
2/3
110
Europe, US
AMX0035, Placebo
Amylyx Pharmaceuticals Inc.
Progressive Supranuclear Palsy, PSP, Neurodegenerative Diseases, Atypical Parkinsonism
04/26
11/29
Zhao, Vivian
ORION, NCT06122662: AMX0035 and Progressive Supranuclear Palsy

Active, not recruiting
2/3
110
Europe, US
AMX0035, Placebo
Amylyx Pharmaceuticals Inc.
Progressive Supranuclear Palsy, PSP, Neurodegenerative Diseases, Atypical Parkinsonism
04/26
11/29
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
LeDoux, Mark S
TOPAZ, NCT03924414: Trial of Parkinson's and Zoledronic Acid

Active, not recruiting
4
2650
US
Zoledronic Acid 5Mg/Bag 100Ml Inj, Reclast, Placebo
California Pacific Medical Center Research Institute, National Institute on Aging (NIA), University of California, San Francisco, Duke University, University of Pittsburgh, Parkinson's Foundation
Parkinson Disease, Osteoporosis, Parkinsonism, Parkinson's Disease and Parkinsonism, Atypical Parkinsonism, Progressive Supranuclear Palsy, Multiple System Atrophy, Vascular Parkinsonism, Dementia with Lewy Bodies
10/25
10/25
NCT05357989 / 2022-001542-38: A Double-blind Study to Investigate Efficacy and Safety of Buntanetap Compared With Placebo in Participants With Early PD

Completed
3
523
Europe, US
buntanetap/posiphen, Posiphen Tartrate, ANVS401, Placebo
Annovis Bio Inc., TFS Trial Form Support
Parkinson's Disease, Idiopathic
12/23
12/23
TEMPO-3, NCT04542499 / 2019-002951-40: Flexible-Dose, Adjunctive Therapy Trial in Adults With Parkinson's Disease With Motor Fluctuations

Completed
3
507
Europe, Canada, US, RoW
Tavapadon, PF-06649751, CVL-751, Placebo
Cerevel Therapeutics, LLC
Parkinson Disease
01/24
02/24
TEMPO-2, NCT04223193 / 2019-002950-22: Flexible-Dose Trial in Early Parkinson's Disease (PD)

Completed
3
304
Europe, US, RoW
Tavapadon, PF-06649751, CVL-751, Placebo
Cerevel Therapeutics, LLC
Parkinson Disease
10/24
10/24
ORION, NCT06122662: AMX0035 and Progressive Supranuclear Palsy

Active, not recruiting
2/3
110
Europe, US
AMX0035, Placebo
Amylyx Pharmaceuticals Inc.
Progressive Supranuclear Palsy, PSP, Neurodegenerative Diseases, Atypical Parkinsonism
04/26
11/29
NCT06006247: Early Parkinson's Disease Monotherapy With CVN424

Completed
2
62
US
CVN424 150 mg, Placebo
Cerevance Beta, Inc.
Parkinson's Disease
01/25
02/25
Isaacson, Stuart
LIGHTHOUSE, NCT05418673 / 2022-000747-77: A Study to Assess if BIIB122 Tablets Are Safe and Can Slow Worsening of Early-Stage Parkinson's Disease in Participants With Specific LRRK2 Genetic Variants Between the Ages of 30 and 80 Using the Movement Disorder Society-Unified Parkinson's Disease Rating Scale

Terminated
3
7
Europe, US
BIIB122, DNL151, BIIB122-Matching Placebo
Biogen, Denali Therapeutics Inc.
Parkinson Disease
07/23
07/23
NCT05357989 / 2022-001542-38: A Double-blind Study to Investigate Efficacy and Safety of Buntanetap Compared With Placebo in Participants With Early PD

Completed
3
523
Europe, US
buntanetap/posiphen, Posiphen Tartrate, ANVS401, Placebo
Annovis Bio Inc., TFS Trial Form Support
Parkinson's Disease, Idiopathic
12/23
12/23
TEMPO-3, NCT04542499 / 2019-002951-40: Flexible-Dose, Adjunctive Therapy Trial in Adults With Parkinson's Disease With Motor Fluctuations

Completed
3
507
Europe, Canada, US, RoW
Tavapadon, PF-06649751, CVL-751, Placebo
Cerevel Therapeutics, LLC
Parkinson Disease
01/24
02/24
TEMPO-1, NCT04201093 / 2019-002949-38: Fixed-Dose Trial in Early Parkinson's Disease (PD)

Completed
3
522
Europe, Canada, US, RoW
Tavapadon, PF-06649751, CVL-751, Placebo
Cerevel Therapeutics, LLC
Parkinson Disease
06/24
06/24
REFOCUS-ALZ, NCT05026177: Simufilam 50 mg or 100 mg for Mild-to-Moderate Alzheimer's Disease

Terminated
3
1125
Canada, US, RoW
Simufilam, PTI-125, Placebo
Cassava Sciences, Inc., Premier Research Group plc
Alzheimer Disease
12/24
12/24
ORION, NCT06122662: AMX0035 and Progressive Supranuclear Palsy

Active, not recruiting
2/3
110
Europe, US
AMX0035, Placebo
Amylyx Pharmaceuticals Inc.
Progressive Supranuclear Palsy, PSP, Neurodegenerative Diseases, Atypical Parkinsonism
04/26
11/29
NCT03655236: PROSEEK: A Phase 2 Study In Early Parkinson's Disease Patients Evaluating The Safety And Efficacy Of Abl Tyrosine Kinase Inhibition Using K0706

Terminated
2
513
Europe, US, RoW
K0706, placebo
Sun Pharma Advanced Research Company Limited
Early Parkinson Disease
04/24
06/24
SHIMMER, NCT05225415: Study to Evaluate the Safety, Tolerability and Efficacy of CT1812 in Subjects with Mild to Moderate Dementia with Lewy Bodies

Completed
2
130
US
CT1812
Cognition Therapeutics, National Institute on Aging (NIA)
Dementia with Lewy Bodies
11/24
11/24
NCT06006247: Early Parkinson's Disease Monotherapy With CVN424

Completed
2
62
US
CVN424 150 mg, Placebo
Cerevance Beta, Inc.
Parkinson's Disease
01/25
02/25
LRRK2-PD, NCT06602193: Safety and Pharmacodynamic Effects of BIIB122 in Participants With LRRK2-Associated Parkinson's Disease

Recruiting
2
50
Europe, US
BIIB122 225 mg, DNL151, BIIB122-Matching Placebo
Denali Therapeutics Inc., Biogen
Parkinson Disease
04/26
02/28
NEULARK, NCT06680830: A Phase 2 Study of NEU-411 in Companion Diagnostic-Positive Participants with Early Parkinson's Disease

Recruiting
2
150
US
NEU-411, Placebo
Neuron23 Inc.
Parkinson Disease, Parkinson, Idiopathic Parkinson Disease, Early Parkinson Disease (Early PD), Parkinson Disease, Idiopathic
09/26
09/27
LUMA, NCT05348785 / 2021-004849-20: A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson's Disease in Adults Between the Ages of 30 and 80

Recruiting
2
640
Europe, Canada, Japan, US, RoW
BIIB122, DNL151, BIIB122-Matching Placebo
Biogen, Denali Therapeutics Inc.
Parkinson Disease
12/25
12/25
NCT05923866: A Phase 2 Study of ONO-2808 in Patients With Multiple System Atrophy

Active, not recruiting
2
92
Japan, US
ONO-2808, Placebo
Ono Pharmaceutical Co. Ltd
Multiple System Atrophy (MSA)
08/25
08/25
ACTIVATE, NCT05819359: Efficacy, Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BIA 28-6156 in GBA-PD

Active, not recruiting
2
237
Europe, Canada, US
BIA 28-6156 10 mg, BIA 28-6156 60 mg, Placebo
Bial R&D Investments, S.A.
Parkinson's Disease
03/26
07/26
NCT04680065: GDNF Gene Therapy for Multiple System Atrophy

Recruiting
1
9
US
AAV2-GDNF gene therapy, Sham (Placebo) Surgery
Brain Neurotherapy Bio, Inc.
Multiple System Atrophy
12/25
12/28
NCT06219629: Parkinson's Disease Progression Study

Active, not recruiting
N/A
82
US
Koneksa Health, Merck Sharp & Dohme LLC, Regeneron Pharmaceuticals
Parkinson Disease
02/26
02/26
TRANQUIL, NCT06235190: Assessment of the Safety and Efficacy of the Felix NeuroAI Wristband in Essential Tremor

Active, not recruiting
N/A
126
US, RoW
Felix NeuroAI Wristband, Sham Device
Fasikl Inc.
Essential Tremor
10/24
11/25
NCT04994015: Parkinson's Foundation PD GENEration Genetic Registry

Recruiting
N/A
25000
Canada, US, RoW
Lab Assay for seven genetic variants for Parkinson's Disease
Parkinson's Foundation, Indiana University, Fulgent Genetics, The Parkinson Study Group
Parkinson's Disease
12/24
06/25
NCT05699460: Pre-Gene Therapy Study in Parkinson's Disease and Multiple System Atrophy

Active, not recruiting
N/A
150
Europe, US
This is an observational study.
Asklepios Biopharmaceutical, Inc.
Parkinson's Disease, Multiple System Atrophy, Parkinson Variant, Multiple System Atrophy
08/25
10/25
ROPAD, NCT03866603: Rostock International Parkinson's Disease Study

Active, not recruiting
N/A
25000
Europe, Canada, US, RoW
CENTOGENE GmbH Rostock
Parkinson´s Disease
12/25
12/25
PPMI, NCT04477785: Clinical - Establishing a Deeply Phenotyped PD Cohort

Recruiting
N/A
4500
Europe, Canada, US, RoW
Michael J. Fox Foundation for Parkinson's Research, Institute for Neurodegenerative Disorders
Parkinson Disease
12/33
12/33
Apetauerova, Diana
ORION, NCT06122662: AMX0035 and Progressive Supranuclear Palsy

Active, not recruiting
2/3
110
Europe, US
AMX0035, Placebo
Amylyx Pharmaceuticals Inc.
Progressive Supranuclear Palsy, PSP, Neurodegenerative Diseases, Atypical Parkinsonism
04/26
11/29
Wszolek, Zbigniew
ORION, NCT06122662: AMX0035 and Progressive Supranuclear Palsy

Active, not recruiting
2/3
110
Europe, US
AMX0035, Placebo
Amylyx Pharmaceuticals Inc.
Progressive Supranuclear Palsy, PSP, Neurodegenerative Diseases, Atypical Parkinsonism
04/26
11/29
NCT05923866: A Phase 2 Study of ONO-2808 in Patients With Multiple System Atrophy

Active, not recruiting
2
92
Japan, US
ONO-2808, Placebo
Ono Pharmaceutical Co. Ltd
Multiple System Atrophy (MSA)
08/25
08/25
NCT04529252: Investigating the Genetic and Phenotypic Presentation of Ataxia and Nucleotide Repeat Diseases

Recruiting
N/A
1000
US
Specimen collection
Mayo Clinic
Spinocerebellar Ataxias, Cerebellar Ataxia, Nucleotide Repeat Disease
12/26
12/26
NCT04503213: A Study to Assess CSF1R-related Leukoencephalopathy After Stem Cell Transplantation

Enrolling by invitation
N/A
20
US
Mayo Clinic
CSF1R-related Leukoencephalopathy, ALSP, POLD, Hematopoietic Stem Cell Transplantation
12/25
12/25
Ly, Helen
NCT05357989 / 2022-001542-38: A Double-blind Study to Investigate Efficacy and Safety of Buntanetap Compared With Placebo in Participants With Early PD

Completed
3
523
Europe, US
buntanetap/posiphen, Posiphen Tartrate, ANVS401, Placebo
Annovis Bio Inc., TFS Trial Form Support
Parkinson's Disease, Idiopathic
12/23
12/23
Laud, Arjun
ORION, NCT06122662: AMX0035 and Progressive Supranuclear Palsy

Active, not recruiting
2/3
110
Europe, US
AMX0035, Placebo
Amylyx Pharmaceuticals Inc.
Progressive Supranuclear Palsy, PSP, Neurodegenerative Diseases, Atypical Parkinsonism
04/26
11/29
NCT05923866: A Phase 2 Study of ONO-2808 in Patients With Multiple System Atrophy

Active, not recruiting
2
92
Japan, US
ONO-2808, Placebo
Ono Pharmaceutical Co. Ltd
Multiple System Atrophy (MSA)
08/25
08/25
ACTIVATE, NCT05819359: Efficacy, Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BIA 28-6156 in GBA-PD

Active, not recruiting
2
237
Europe, Canada, US
BIA 28-6156 10 mg, BIA 28-6156 60 mg, Placebo
Bial R&D Investments, S.A.
Parkinson's Disease
03/26
07/26
Holms, Freddrenia
ORION, NCT06122662: AMX0035 and Progressive Supranuclear Palsy

Active, not recruiting
2/3
110
Europe, US
AMX0035, Placebo
Amylyx Pharmaceuticals Inc.
Progressive Supranuclear Palsy, PSP, Neurodegenerative Diseases, Atypical Parkinsonism
04/26
11/29
Zhao, Vivian
ORION, NCT06122662: AMX0035 and Progressive Supranuclear Palsy

Active, not recruiting
2/3
110
Europe, US
AMX0035, Placebo
Amylyx Pharmaceuticals Inc.
Progressive Supranuclear Palsy, PSP, Neurodegenerative Diseases, Atypical Parkinsonism
04/26
11/29

Download Options